What are the AASLD guidelines for the treatment of cirrhosis and hepatitis B (HBV) (Hep B)?

Updated: Jun 08, 2021
  • Author: Nikolaos T Pyrsopoulos, MD, PhD, MBA, FACP, AGAF; Chief Editor: BS Anand, MD  more...
  • Print

In adults with compensated cirrhosis and low levels of viremia (<2,000 IU/mL), regardless of ALT level, the AASLD suggests antiviral therapy (preferred: tenofovir, entecavir) to reduce the risk of decompensation. (Conditional recommendation).

Note the following:

  • If therapy is discontinued, closely monitor patients for a minimum of every 3 months for at least 1 year to detect early signs of viral rebound that may lead to decompensation.
  • In those not offered treatment, closely monitor every 3-6 months for an elevation in HBV DNA level and/or clinical decompensation; initiate treatment in these settings.
  • Patients with compensated cirrhosis and high HBV DNA levels (>2,000 U/mL) are treated according to the recommendations for HBeAg-positive and -negative immune-active chronic hepatitis B.

For HBsAg-positive adults with decompensated cirrhosis, the AASLD recommends indefinite antiviral therapy (preferred: entecavir, tenofovir) to reduce the risk of worsening liver-related complications, regardless of HBV DNA level, HBeAg status, or ALT level. (Strong recommendation) Also consider liver transplantation for eligible candidates.

Did this answer your question?
Additional feedback? (Optional)
Thank you for your feedback!